TITLE:
A Retrospective Evaluation of Chemotherapy Regimens in Unselected Patients with Metastatic Non-Small Cell Lung Cancer
AUTHORS:
Ahmed Ashour Badawy, Abbas Omar, Waleed Arafat, Gehan Khedr, Sejong Bae, Stefan Grant
KEYWORDS:
NSCLC-Lung Cancer Chemotherapy-Comorbidities
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.3,
March
28,
2018
ABSTRACT: Background: Randomized clinical trials
have demonstrated the benefits of chemotherapy in carefully selected non-small cell
lung cancer (NSCLC) patients. How generalizable
these results are to other NSCLC patients is unresolved. Methods: The outcomes
of patients treated with standard chemotherapy regimens (paclitaxel / carboplatin;
gemcitabine / carboplatin; pemetrexed / carboplatin; paclitaxel / carboplatin / bevacizumab)
off study as first line therapy between 2002 and 2012 at our institution were compared
to the reported results of trials supporting the FDA approval of these drugs and/or
regimens. Results: In our population, 38.1% of the patients had hypertension,
11.9% of the patients were diabetic, 23.7% had chronic obstructive pulmonary disease
(COPD), 11.9% had coronary artery disease (CAD) and 2.1% had renal or liver disease.
Notably, the presence of a single or multiple comorbidities was associated with
low overall survival compared to matched patients with no comorbidities (p = 0.007). Conclusion: The presence of single or multiple comorbidities is associated with inferior overall survival compared to
matched groups without such pre-existing conditions.